Mitsubishi UFJ Trust & Banking
CRSP icon

Mitsubishi UFJ Trust & Banking’s CRISPR Therapeutics CRSP Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$341K Buy
+6,255
New +$330K ﹤0.01% 1182
2024
Q4 		– Sell
-31,433
Closed -$1.48M – 1055
2024
Q3 		$1.48M Sell
31,433
-1,777
-5% -$90.2K ﹤0.01% 867
2024
Q2 		$1.79M Sell
33,210
-6,460
-16% -$374K ﹤0.01% 803
2024
Q1 		$2.7M Sell
39,670
-2,490
-6% -$178K 0.01% 754
2023
Q4 		$2.64M Sell
42,160
-6,360
-13% -$352K 0.01% 754
2023
Q3 		$2.2M Buy
48,520
+19,230
+66% +$993K 0.01% 776
2023
Q2 		$1.64M Sell
29,290
-1,680
-5% -$95.3K ﹤0.01% 788
2023
Q1 		$1.4M Hold
30,970
– – ﹤0.01% 795
2022
Q4 		$1.26M Hold
30,970
– – ﹤0.01% 807
2022
Q3 		$2.02M Buy
+30,970
New +$2.24M 0.01% 763

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's CRSP Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 6,255 shares worth $341K. The stake represents ﹤0.01% of the portfolio and ranks #1182 among its holdings. This is a return to the name: Mitsubishi UFJ Trust & Banking previously reported a position in CRSP as recently as Q3 2024.

Mitsubishi UFJ Trust & Banking first reported a position in CRSP in Q3 2022 and has held it in 10 quarters since. The position peaked at $2.7M in Q1 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Mitsubishi UFJ Trust & Banking held 6,255 shares of CRISPR Therapeutics worth $341K as of Q2 2026.
  • CRISPR Therapeutics was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1182 holding.
  • Mitsubishi UFJ Trust & Banking first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 10 quarters since.
  • Mitsubishi UFJ Trust & Banking's CRISPR Therapeutics position peaked at $2.7M in Q1 2024.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.